Brief: Bioinvent Completes Planned Dose-Escalation

BioInvent International AB

06/09/2022 11:34

Sept 6 (Reuters) - BioInvent International AB  BINV.ST :
    * COMPLETES THE PLANNED DOSE-ESCALATION IN PHASE 1/2A TRIAL
OF
BI-1808 IN ADVANCED MALIGNANCIES
    * BI-1808 SHOWN TO BE SAFE AND WELL TOLERATED WITH NO
SERIOUS
ADVERSE EVENTS OBSERVED
    * GIVEN POSITIVE SAFETY AND TOLERABILITY PROFILE, HIGHER
DOSES
WILL BE EXPLORED
    * THREE DISEASE STABILIZATIONS OBSERVED DURING ESCALATION
PROCESS
    * COHORT TO EXPLORE POTENTIAL SYNERGISTIC ACTIVITY IN
COMBINATION
WITH KEYTRUDA® IS NOW ENROLLING PATIENTS

Source text for Eikon:  ID:nMFN5K245Z 
Further company coverage:  BINV.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))